Bhubaneswar: CBI on Sunday registered a case against an employee of National Council for Cement and Building Materials (NCB) here for allegedly demanding a Rs 3,000 bribe from a contractor to issue him a favourable testing report for cement used for construction. The incident comes close on the heels of the arrest of a high-ranking officer of the Bridge and Roof Company, a central PSU, on bribery charges on Dec 7. NCB, an apex research and development organisation under the ministry of commerce and industry, is dedicated to research, technology development, education and industrial services for cement, allied building materials and construction industries. Accused Brijesh Dash is posted in NCB's branch in Mancheswar area here. According to contractor Sujit Kumar Jena's complaint, he recently completed work of laying cover slab in ward no. 19 in Choudwar municipality at a cost of Rs 4,45,443. Following standard protocol, the construction slab (testing cube) required NCB testing post-completion. "After receipt of a positive testing report from NCB, the Choudwar municipality will clear my payment bill. After depositing a requisite amount for the testing, I deposited the cube in the NCB office on Dec 24. Dash received the cube," Jena's complaint stated. Subsequently, Dash obtained contact details of Jena's son, his work assistant. On Dec 26, Dash contacted Jena's son and allegedly requested Rs 3,000 for issuing a favourable test report. "I contacted Brijesh Dash. He placed the same demand before me. I expressed my inability to pay the bribe. He kept on calling me for the bribe. Dash shared a UPI number to receive the bribe," the complaint read. "We have registered a case under Section 7 of the Prevention of Corruption Act, 1988 (amended in 2018) against the NCB employee for demanding the bribe. Investigation is in progress," a CBI source stated. No arrests have been made yet. Stay updated with the latest news on Times of India . Don't miss the yearly horoscope 2025 and Chinese horoscope 2025 for Rat , Ox , Tiger , Rabbit , Dragon , Snake , Horse , Goat , Monkey , Rooster , Dog , and Pig zodiac signs. Spread love this holiday season with these New Year wishes and messages .T he Lonely City by Olivia Laing looks at loneliness in its emotional and psychological dimensions, using New York City as a metaphor for isolation. The book is half-memoir, but also delves into the lives of the city’s most compelling artists — Andy Warhol, Edward Hopper and David Wojnarowicz — all of whom used art to explore their own feelings of isolation and the attendant ugliness. Laing emphasises that loneliness is about the emotional distance between people, often exacerbated by modern society’s emphasis on individualism. As grief and isolation became the norm during the pandemic, different people navigated the storm of their emotions in different ways. The COVID-19 pandemic and multiple lockdowns promoted remote work culture and social distancing has scarred people socially in different ways. For Arunima Singhal, 20, the pandemic was one of the darkest times of her life. Her family grappled with a deep wedge of isolation, each member waking up, doing the chores only to go back to sleep. “There seemed to be barely any point reaching out to people because I wasn’t sure what to talk about. I remember it just really felt like I had to push myself to exist.” Many people also find it hard to remember the person that they were prior to the pandemic, which forms the passageway to feelings of guilt, depersonalisation, and detachment. “I finally started to understand Pink Floyd’s Comfortably Numb,” says Singhal, as she laughs. Tanishqa Mathur, 24, talks about how the pandemic felt like it was a whole other world. “Even though my friend and I found different ways to stay in touch (like watching online movies), we couldn’t trust the reality of virtual connections, and since there was no certainty as to when or if the pandemic would end, loneliness held a sort of gravity.” Now, she says, the pandemic changed how she views all of her relationships with her friends and her romantic partners. The absolute physical isolation seems to have hit several people hard. The loss of touch beckoned people to go online and look at peoples’ lives voyeuristically whilst barely making an effort to change their own. Gen Z is also one of the first generations to fully grow up with so much technology at the press of a button, which seems to have acted as a catalyst to enable things to spiral out of control. While grief and isolation became prevalent in COVID era, it’s aftermath still persists in various ways. Though screens have bridged the distances amongst people, it has also left people emotionally drained. “Many people are now connecting online, but these interactions lack the warmth of face-to-face contact, leaving people feeling detached,” says a Mumbai-based psychotherapist, Neha Mehta. Loneliness has come across a public health crisis in the past few years and is often linked with suicide, mental health disorders and substance abuse. Many school and college students are struggling to adjust and reconnect with their peers after two years of online learning. The increasing consumption of social media and digital interactions during the COVID era has left many people, especially the youth feeling a sense of “digital isolation.” WHO estimated that 10% of adolescents and 25% of old people in India are alone. India’s loneliness epidemic is not only a mental health crisis, it has also come across as a societal challenge threatening social connections and bonds among people. madhumitasharma9318@gmail.com treya.sinha@gmail.com Published - November 24, 2024 02:27 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp RedditWhy releasing Aaron Rodgers now may not be New York Jets' best option | Sporting NewsJLR announces Defender Dakar program
On a bitterly cold Tyneside night West Ham finally remembered how to fight back. Even better for their beleaguered manager, Julen Lopetegui, a team inspired by standout performances from Tomas Soucek and Jarrod Bowen exhibited the sort of ruthless precision strangely absent from Newcastle’s game. Expertly taken goals from Soucek and Aaron Wan-Bissaka reinforced Lopetegui’s fragile job security, lifting West Ham to 14th , three points behind Eddie Howe’s team, as Newcastle’s hopes of Champions League qualification sustained a dent. Before a potentially tenure-defining match, Lopetegui took time to revisit the bronze statue of Sir Bobby Robson that stands just outside St James’ Park. During his days as a goalkeeper, West Ham’s manager played under Robson at Barcelona and learned a lot from him. Three decades on and with his team three points clear of the relegation zone at kick-off, Lopetegui desperately needed to coax the sort of performance Robson would have treasured from his West Ham players here. Although the east London club rarely change managers mid-season there were strong suggestions that the former Spain coach’s future hinged on his team’s performance on Tyneside and then at home against Arsenal on Saturday. Lopetegui knew that, with the former Borussia Dortmund coach Edin Terzic among those reportedly waiting in the wings, a heavy defeat could ruin his hopes of surviving until at least the weekend but, for once, the manager was not the only one in the firing line. Tim Steidten, West Ham’s technical director, is primarily responsible for the summer’s £100m-plus spending splurge and now finds himself under forensic scrutiny. Undeterred by all this off-field politicking, Soucek revelled in placing Howe’s defence under an unflattering microscope as, completely unmarked, he headed Lopetegui’s side into a 10th-minute lead following Emerson’s fine corner. With Lloyd Kelly suffering an alarming concentration lapse, Newcastle suddenly felt the suspended Dan Burn’s absence. They had been on top, with Alexander Isak having an early goal disallowed for offside but, despite subsequently spurning a series of half chances, Howe’s players were frustrated by Lopetegui’s five-man midfield. With the tension rising, West Ham’s manager received a yellow card for dissent after his lively left winger, Crysencio Summerville, was contentiously adjudged to have fouled Sean Longstaff. Given it was the Spaniard’s third booking of the season, he must now watch the Arsenal game from the stands while serving a one-game touchline ban. Howe’s decision to start Joelinton on the right rather than the left wing did not work well. The idea was presumably to offer Anthony Gordon the freedom of his preferred left flank but the England winger let himself down when he shot straight at Lukasz Fabianski, allowing the goalkeeper to save smartly with a leg, following Jean-Clair Todibo’s defensive error. The second period began with a relocation for Joelinton to midfield as Howe introduced Harvey Barnes wide on the left. Sign up to Football Daily Kick off your evenings with the Guardian's take on the world of football after newsletter promotion Barnes impressed but, unfortunately for Howe, his presence served to persuade Soucek and Bowen to redouble their efforts. While Soucek strained every sinew to hold his midfield together, Bowen showed off quick feet and an even faster brain down the right. Bowen played a key role in West Ham doubling their advantage after Lucas Paquetá pinched possession from Bruno Guimarães and played in the England forward. All that remained was for a player much admired by Howe to set up Aaron Wan-Bissaka on the underlap, leaving the right-back to take a touch before evading Nick Pope’s reach courtesy of a shot that brushed a post en route to the back of the net. It was only the third goal of Wan-Bissaka’s career. It proved the signal for Callum Wilson to step off the home bench for his first appearance of another injury-blighted season. He had scored 12 goals in 14 previous appearances against West Ham and quickly saw a penalty appeal rejected, but this was Lopetegui’s night and even Wilson could not spoil it.
An Iranian journalist's travel to China: Chinese modernization amazes me
KyKy Tandy, FAU close out Oklahoma State in Charleston“They showed me a lot of love. ... How they're going to make it comfortable for me,” he said. "That's one of the things I was looking for." Soto was introduced at Citi Field a day after his deal was finalized. Speaking in the Piazza 31 Club, he was flanked by Mets owner Steve Cohen, president of baseball operations David Stearns and his agent, Scott Boras. “They always talk about family. They always talk about stick(ing) together,” Soto said. “That's one of the things that opened my eyes.” Security men in gray suits wearing earpieces were off to the side. Soto walked in led by Boras, wearing a dark suit, black turtle neck shirt and gold chain with his No. 22. “I’m excited by the Mets future,” Cohen said. “I think this accelerates our goal of winning championships.” Soto chose the Mets' offer on Sunday, deciding to leave the Yankees after helping them reach the World Series in his only season in the Bronx. Adames plans to play every day for Giants SAN FRANCISCO — Willy Adames wasted little time making one thing clear: He wants to play all 162 games for the San Francisco Giants. So when introduced as their new shortstop Thursday, Adames looked to his left and gently put a hand on manager Bob Melvin's right shoulder, smiled and said, “if he lets me.” Melvin might not need much convincing, thrilled to suddenly have stability at a position that lacked continuity this year in his first season as skipper. Adames didn't hesitate to also offer a thought to new boss Buster Posey: He plans to win a few championships with the Giants just like the catcher-turned-executive did here. Surrounded by his parents and other family and friends, Adames was formally introduced and welcomed at Oracle Park after signing a $182 million, seven-year contract — the first big, splashy move made by Posey since he became President of Baseball Operations in late September. “There’s no words to describe my feeling right now to be here in this beautiful city, I’m just so happy to be here,” Adames said. "... This is a dream come true for me. I’m thrilled to be here, I’m so excited. Hopefully we can win a few championships like you did, and that’s one of the main reasons I’m here.” Franco trial delayed five months PUERTO PLATA, Dominican Republic — The trial against Tampa Bay Rays shortstop Wander Franco, who has been charged with sexually abusing a minor, sexual and commercial exploitation against a minor, and human trafficking, was postponed on Thursday and scheduled to resume June 2, 2025. Dominican judge Yacaira Veras postponed the hearing at the request of prosecutors because of the absence of several key witnesses in the case. Only three out of 31 witnesses arrived to the hearing on Thursday. Franco’s lawyers asked the court to reconsider the postponement, arguing Franco must report to spring training in mid-February. “There is no case against Wander, for as many witnesses as they present, there is no case now,” Franco's lead lawyer Teodosio Jáquez told The Associated Press after the hearing. The judge replied that Franco is obligated to continue with the trial schedule and his conditional release from detainment.NEW YORK — Juan Soto put on a New York Mets jersey and cap for the first time Thursday after his record $765 million, 15-year contract was finalized and talked about what made the difference in his decision. “They showed me a lot of love. ... How they're going to make it comfortable for me,” he said. "That's one of the things I was looking for." Soto was introduced at Citi Field a day after his deal was finalized. Speaking in the Piazza 31 Club, he was flanked by Mets owner Steve Cohen, president of baseball operations David Stearns and his agent, Scott Boras. “They always talk about family. They always talk about stick(ing) together,” Soto said. “That's one of the things that opened my eyes.” Security men in gray suits wearing earpieces were off to the side. People are also reading... Soto walked in led by Boras, wearing a dark suit, black turtle neck shirt and gold chain with his No. 22. “I’m excited by the Mets future,” Cohen said. “I think this accelerates our goal of winning championships.” Soto chose the Mets' offer on Sunday, deciding to leave the Yankees after helping them reach the World Series in his only season in the Bronx. Adames plans to play every day for Giants SAN FRANCISCO — Willy Adames wasted little time making one thing clear: He wants to play all 162 games for the San Francisco Giants. So when introduced as their new shortstop Thursday, Adames looked to his left and gently put a hand on manager Bob Melvin's right shoulder, smiled and said, “if he lets me.” Melvin might not need much convincing, thrilled to suddenly have stability at a position that lacked continuity this year in his first season as skipper. Adames didn't hesitate to also offer a thought to new boss Buster Posey: He plans to win a few championships with the Giants just like the catcher-turned-executive did here. Surrounded by his parents and other family and friends, Adames was formally introduced and welcomed at Oracle Park after signing a $182 million, seven-year contract — the first big, splashy move made by Posey since he became President of Baseball Operations in late September. “There’s no words to describe my feeling right now to be here in this beautiful city, I’m just so happy to be here,” Adames said. "... This is a dream come true for me. I’m thrilled to be here, I’m so excited. Hopefully we can win a few championships like you did, and that’s one of the main reasons I’m here.” Franco trial delayed five months PUERTO PLATA, Dominican Republic — The trial against Tampa Bay Rays shortstop Wander Franco, who has been charged with sexually abusing a minor, sexual and commercial exploitation against a minor, and human trafficking, was postponed on Thursday and scheduled to resume June 2, 2025. Dominican judge Yacaira Veras postponed the hearing at the request of prosecutors because of the absence of several key witnesses in the case. Only three out of 31 witnesses arrived to the hearing on Thursday. Franco’s lawyers asked the court to reconsider the postponement, arguing Franco must report to spring training in mid-February. “There is no case against Wander, for as many witnesses as they present, there is no case now,” Franco's lead lawyer Teodosio Jáquez told The Associated Press after the hearing. The judge replied that Franco is obligated to continue with the trial schedule and his conditional release from detainment. Be the first to know
HERZLIYA, Israel and CALGARY, Alberta , Dec. 12, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF ) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio. During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT - CBD ( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LPT-CBD as a treatment for chronic pain in humans. Additionally, the FDA acknowledged LPT-CBD's development under the 505(b)(2) regulatory pathway, which provides Innocan with an accelerated route to patent utilization and commercialization. On the veterinary front, LPT-CBD's innovation was recognized by the FDA's Center for Veterinary Medicine (CVM), which granted Innocan a fee waiver for 2024 and issued a number that identifies an Investigational New Animal Drug (INAD). This designation allows Innocan to facilitate correspondence and data exchange with the CVM to support the development of LPT-CBD as a new veterinary drug. Iris Bincovich, CEO of Innocan Pharma, commented: "In 2024, we not only met but surpassed our FDA-related goals, achieving regulatory milestones ahead of schedule. With the FDA 505(b)(2) regulatory pathway meeting behind us, these advancements position us to accelerate our development in 2025, bringing us closer to delivering innovative pain management solutions for both human and veterinary applications." The 505(b)(2) FDA regulatory pathway offers a streamlined approach for developing a long-acting injectable cannabinoid using a liposomal drug delivery platform to treat chronic pain. By leveraging existing pre-clinical data from approved products, this pathway is expected to significantly shorten both development time and cost. This pathway facilitates innovative formulations like liposomal delivery, by allowing for modifications to dosage forms, administration routes, or drug combinations, all while adhering to stringent safety and efficacy standards. This approach is expected to accelerate market entry and address unmet medical needs in chronic pain management. Company ' s Update on its Activity in Research and Development and FDA interactions On February 26, 2024 , the Company announced the latest findings from the Company's pharmacokinetic study of its liposome CBD platform ("LPT-CBD") in rabbits. In agreement with studies conducted in other animals (mice, dogs, goats, and sheep) this study resulted in prolonged exposure of CBD obtained following a single subcutaneous LPT-CBD injection. This data along with data obtained from other organisms injected with the Company's liposomal CBD, consistently demonstrates that a detectable CBD level could be maintained for weeks following a single injection. On March 5, 2024 , the Company announced the results of a recent tissue distribution study of its liposome CBD platform (LPT-CBD), that indicated the potential of LPT-CBD to support a new therapeutic venue for neurological disorders. In this study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them. LPT technology provides a long presence of CBD in the blood enabling CBD to pass the blood brain barrier (BBB) and deliver long brain exposure. On April 22, 2024 , the Company announced that it had submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for LPT-CBD. Innocan's Pre-IND meeting request letter to the FDA represents a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans. The objective of the Pre-IND meeting is to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an investigational new drug ("IND") program in the United States . On May 9, 2024 , the Company announced the successful pre-clinical treatment of amputee female donkey with a liposomal-CBD injection. Miri, a-7-year-old female donkey, had undergone amputation of her right front limb, leaving the weight burden primarily on her left front limb. This led to an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. In a compassionate act, Miri was administered a liposomal-CBD injection. The effect was immediate as Miri regained her ability to walk and move as she had before her inflammatory disease developed. On May 21, 2024 , the Company announced significant advancements in the regulatory process for its LPT - CBD, which provides an innovative solution in non-opioid pain management. The FDA granted Innocan an INAD number and approved an initial meeting with the Company to discuss the strategic path forward. The meeting with the FDA was on July 31, 2024 , where Innocan presented its preclinical results and proposed clinical development plan. The meeting is key to launching human clinical trials for the LPT-CBD injectable drug, developed to provide a novel treatment option for chronic pain. On June 11, 2024 , the Company announced the success and conclusion of a preliminary safety evaluation of Innocan's single injection and sustained-release LPT-CBD conducted on minipigs. Recognized by the FDA as an excellent model for toxicology, minipigs are small breeds of miniature domestic pigs which share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. The animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions. On July 2, 2024 , the Company announced that it engaged the Past President of the Eastern Pain Association, Dr. William K. Schmidt , to support its LPT-CBD submission process to the FDA for chronic pain. His extensive expertise in pain-related clinical development and regulatory affairs will strongly contribute to Innocan's team during the LPT-CBD submission process with the FDA. Dr. Schmidt brings over 25 years of pharmaceutical industry clinical trial experience, specializing in analgesic and narcotic antagonist drug development. On July 26, 2024 , the Company announced that the CVM) granted the Company a sponsor fee waiver and assigned an INAD number for its LPT-CBD product. This represented a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug. The Company further announced that following the assessment of LPT-CBD's scientific package, the CVM recognized Innocan's contribution to pursuing innovative animal drug products and technology and granted the Company a sponsor fee waiver for fiscal year 2024. Over the past year, repeated administration of LPT-CBD in dogs and other animals demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application. On September 3, 2024 , the Company announced that it received a positive response from the FDA following Innocan's successful pre-IND Type B meeting with the FDA held in July, for its lead drug product LPT-CBD. The FDA has agreed to LPT-CBD's submission under the 505(b)(2) New Drug Application (NDA) by establishing a scientific bridge to the reference listed drug. The 505(b)(2) abbreviated pathway, as it is often described, typically enables a faster route to patent utilization and commercial approval. This pathway is a significant milestone for Innocan, as it may pave the way for a streamlined and accelerated FDA approval process for LPT-CBD, while allowing Innocan to advance its patent protected innovation. In addition, Innocan has reached an alignment with the FDA on both its non-clinical development plan and the clinical study design for LPT-CBD's proposed IND filing for a Phase I clinical study. On October 9, 2024 , The Company announced that Dr. Joseph V. Pergolizzi, Jr. , M.D., a member of the Company's Scientific Advisory Board, was recognized among the top 2% most cited scientists in the world in a new list published by Stanford University . This achievement underscores Dr. Pergolizzi's long-term contribution to medical science and his influential role in shaping global healthcare practices. Dr. Pergolizzi was appointed to be part of Innocan's Scientific Advisory Board in September 2023 . His role focuses on promoting pharmaceutical human product R&D and supporting the Company's planned FDA filing for new medications. His expertise in pain management, critical care medicine, and regulatory processes are key in advancing the issuer's pharmaceutical developments. On October 11, 2024 , the Company announced promising results from a multi-year compassionate therapy using repeated LPT-CBD injections for pain relief in dogs with naturally occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals. In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs (NSAIDs) and oral CBD, showed noticeable pain relief, substantially improved mobility and increased well-being which was clearly noticeable. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years, respectively after their owners reported significant improvement in quality of life, receiving the treatment in addition to other conventional treatments. About Innocan Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd. which focuses on advanced, targeted online sales. www.innocanpharma.com For further information, please contact: Iris Bincovich, CEO +1-516-210-4025 +972-54-3012842 +44 203 769 9377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Cautionary note regarding forward-looking information Certain information set forth in this news release, including, without limitation, information regarding research and development, collaborations, the filing of potential applications with the FDA and other regulatory authorities, the potential achievement of future regulatory milestones, the potential for treatment of conditions and other therapeutic effects resulting from research activities and/or the Company's products, requisite regulatory approvals and the timing for market entry and potential for patent utilization and commercialization is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact Innocan can also be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedar.com . Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward looking information as a result of any new information, future events or otherwise, except as may be required by applicable law. Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg SOURCE Innocan Pharma CorporationSport Safety and Security Training and Advanced Education Programme for Asian nationsNone
Former Clovis Superintendent Says She’s Running for County Schools SuperintendentThe NFC’s No. 1 seed will come down to the final week when the Detroit Lions host the Minnesota Vikings. The winner takes the NFC North and gets a first-round playoff bye and home-field advantage until the Super Bowl. The loser becomes the No. 5 seed and must play on the road in the wild-card round. The Vikings (14-2) held on for a 27-25 victory over the Green Bay Packers to set up the high-stakes showdown in Week 18. The Lions (13-2) visit the San Francisco 49ers (6-9) on Monday night in a rematch of the NFC title game. Win, lose or tie, they have to beat the Vikings again. Detroit beat Minnesota 31-29 in Week 7. The Philadelphia Eagles clinched the NFC East and locked up the No. 2 seed with a 41-7 rout of the Dallas Cowboys. However, coach Nick Sirianni has a tough decision to make this week. Saquon Barkley is 101 yards away from breaking Eric Dickerson’s single-season record for yards rushing in a season. Sirianni has to decide whether to rest Barkley and most of his starters to prepare for the playoffs or let his star try for the 40-year-old record. The Los Angeles Rams (10-6) were on the verge of clinching the NFC West. They would lock it up Sunday night if the Commanders beat the Falcons. The outcome of the Atlanta-Washington game has a major impact on the Tampa Bay Buccaneers (9-7). If the Falcons win, they’d remain first in the NFC South and would win the division with a victory against Carolina next week. If the Falcons lose, the Buccaneers would take over first place and would secure the division with a victory over New Orleans next week. The Commanders would secure a wild-card spot with a win against Atlanta. If they lose, Seattle stays mathematically alive for a wild card and the Buccaneers could also find a path to the playoffs as a wild-card team. Three teams in the AFC have already secured their seeds. The two-time defending Super Bowl champion Kansas City Chiefs (15-1) won the AFC West weeks ago and clinched the No. 1 seed. The AFC East champion Buffalo Bills (13-3) are the No. 2 seed. The AFC South champion Houston Texans (9-7) are the No. 4 seed. The Baltimore Ravens (11-5) would win the AFC North and get the No. 3 seed with a win or tie against Cleveland next weekend or a loss or tie by Pittsburgh, which hosts Cincinnati. If they don’t win the division, the Steelers have already clinched a wild-card berth. The Los Angeles Chargers (10-6) also secured a wild-card spot. They’ll be no lower than the sixth seed. The final AFC playoff spot comes down to the Broncos (9-7), Dolphins (8-8) or Bengals (8-8). Denver clinches with a win or tie against the Chiefs. The Dolphins need the Broncos to lose and they must beat the Jets on the road to get in. The Bengals must win and the Broncos and Dolphins have to lose for them to get in. ___ AP NFL: https://apnews.com/hub/NFL Rob Maaddi, The Associated Press
WILMINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM ), a leader in A.I.-enabled robotics technology for the supply chain, today announced that it has completed the acquisition of OhmniLabs, a Silicon Valley-based innovator in the field of robotics solutions for health care. “Combining Symbotic’s expertise in large-scale automation with OhmniLabs’ ground-breaking mobile robots, vision and A.I. solutions will enable the development of unparalleled automation innovations across different settings,” said Rick Cohen, Executive Chairman and CEO of Symbotic. “We were drawn to OhmniLabs for its impressive talent and industry experience that will enable our expansion beyond the four walls of the warehouse.” Founded in 2015 by robotics experts, OhmniLabs has pioneered a fully in-house development and manufacturing model, enabling rapid innovation and speed-to-market for cutting-edge robotics solutions. The company is best known for its autonomous disinfection and telepresence robots, which create safer and healthier environments globally. With the strategic acquisition of OhmniLabs’ industry expertise and talented robotics team, Symbotic will be better positioned to both expand its leading automation capabilities for supply chain customers while delivering enhanced innovation to customers in the health care industry. “OhmniLabs’ mission has been to develop meaningful robotics to provide real-world solutions, and we have made significant progress with the support of our loyal team members and customers. Being a part of Symbotic, a true leader in robotics innovation, will propel this vision forward to deliver cutting-edge solutions that redefine what’s possible in health care, logistics and beyond,” said Jared Go, Co-founder and CTO, OhmniLabs. ABOUT SYMBOTIC Symbotic is an automation technology leader reimagining the supply chain with its end-to-end, A.I.-powered robotic and software platform. Symbotic reinvents the warehouse as a strategic asset for the world’s largest retail, wholesale, and food & beverage companies. Applying next-generation technology, high-density storage and machine learning to solve today's complex distribution challenges, Symbotic enables companies to move goods with unmatched speed, agility, accuracy and efficiency. As the backbone of commerce, Symbotic transforms the flow of goods and the economics of the supply chain for its customers. For more information, visit www.symbotic.com . FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about Symbotic’s acquisition of substantially all of the assets of OhmniLabs and Symbotic’s expectations or predictions of future financial or business performance or conditions. Such forward-looking statements involve risks and uncertainties that may cause actual events, results or performance to differ materially from those indicated by such statements. Certain of these risks are identified and discussed in Symbotic’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 4, 2024. These forward-looking statements are expressed in good faith, and Symbotic believes there is a reasonable basis for them. However, there can be no assurance that the events, results or trends identified in these forward-looking statements will occur or be achieved. Forward-looking statements speak only as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. Symbotic is not under any obligation, and expressly disclaims any obligation to update, alter or otherwise revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Readers should carefully review the statements set forth in the reports that Symbotic has filed or will file from time to time with the SEC. INVESTOR RELATIONS CONTACT Charlie Anderson Vice President, Investor Relations & Corporate Development ir@symbotic.com MEDIA INQUIRIES mediainquiry@symbotic.comLOS ANGELES (AP) — The Biden administration plans on reducing part of Intel's $8.5 billion in federal funding for computer chip plants around the country, according to three people familiar with the grant who spoke on the condition of anonymity to discuss private conversations. The reduction is largely a byproduct of the $3 billion that Intel is also receiving to provide computer chips to the military. President Joe Biden announced the agreement to provide Intel with up to $8.5 billion in direct funding and $11 billion in loans in March. The changes to Intel’s funding are not related to the company’s financial record or milestones, the people familiar with the grant told The Associated Press. In August, the chipmaker announced that it would cut 15% of its workforce — about 15,000 jobs — in an attempt to turn its business around to compete with more successful rivals like Nvidia and AMD. Unlike some of its rivals, Intel manufactures chips in addition to designing them. Two years ago, President Biden hailed Intel as a job creator with its plans to open a new plant near Columbus, Ohio. The president praised the company for plans to “build a workforce of the future” for the $20 billion project, which he said would generate 7,000 construction jobs and 3,000 full-time jobs set to pay an average of $135,000 a year. The California-based tech giant's funding is tied to a sweeping 2022 law that President Biden has celebrated and which is designed to revive U.S. semiconductor manufacturing. Known as the CHIPS and Science Act , the $280 billion package is aimed at sharpening the U.S. edge in military technology and manufacturing while minimizing the kinds of supply disruptions that occurred in 2021, after the start of the coronavirus pandemic, when a shortage of chips stalled factory assembly lines and fueled inflation . The Biden administration helped shepherd the legislation following pandemic-era concerns that the loss of access to chips made in Asia could plunge the U.S. economy into recession. When pushing for the investment, lawmakers expressed concern about efforts by China to control Taiwan, which accounts for more than 90% of advanced computer chip production. In August, the administration pledged to provide up to $6.6 billion so that a Taiwanese semiconductor giant could expand the facilities it is already building in Arizona and better ensure that the most advanced microchips are produced domestically for the first time. The Commerce Department said the funding for Taiwan Semiconductor Manufacturing Co. meant the company could expand on its existing plans for two facilities in Phoenix and add a third, newly announced production hub. The administration has promised tens of billions of dollars to support construction of U.S. chip foundries and reduce reliance on Asian suppliers, which Washington sees as a security weakness. _____ Boak reported from Washington. Josh Boak And Sarah Parvini, The Associated Press
Stock market today: Nasdaq hits a record as Wall Street drifts ahead of Federal Reserve's meeting7 Steps to Help Keep Your Small Business Cyber Safe This Holiday Season
Amentum Reports Fiscal Year 2024 Results and Affirms its Fiscal Year 2025 Guidance